Literature DB >> 16198974

Targeted treatment: insights from studies of osteopontin and hypoxia.

Richard P Hill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16198974     DOI： 10.1016/S1470-2045(05)70363-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

2.  Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.

Authors:  Quynh-Thu Le; Richard Fisher; Kelly S Oliner; Richard J Young; Hongbin Cao; Christina Kong; Edward Graves; Rodney J Hicks; Grant A McArthur; Lester Peters; Brian O'Sullivan; Amato Giaccia; Danny Rischin
Journal:  Clin Cancer Res       Date:  2012-03-01       Impact factor: 12.531

Review 3.  Clinical biomarkers for hypoxia targeting.

Authors:  Quynh-Thu Le; Don Courter
Journal:  Cancer Metastasis Rev       Date:  2008-09       Impact factor: 9.264

4.  Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.

Authors:  Timothy D Solberg; Jessica Nearman; John Mullins; Sicong Li; Janina Baranowska-Kortylewicz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-11-01       Impact factor: 7.038
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.